Bavencio 200 mg/10 mL (20 mg/mL) injection Images
Generic Name: avelumab
This medication has been identified as Bavencio 200 mg/10 mL (20 mg/mL) injection. It is supplied by EMD Serono, Inc.
Bavencio is used in the treatment of Urothelial Carcinoma; Merkel Cell Carcinoma; Renal Cell Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Bavencio 200 mg/10 mL (20 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Bavencio
- Generic Name
- avelumab
- Strength
- 200 mg/10 mL (20 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- EMD Serono, Inc.
- National Drug Code (NDC)
- 44087-3535
More about Bavencio (avelumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.